董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Anthony M. Manning | 男 | Director | 61 | 14.00万美元 | 未持股 | 2023-06-20 |
| Alan W. Dunton | 男 | Director | 69 | 15.50万美元 | 未持股 | 2023-06-20 |
| Carl Spana | 男 | Chief Executive Officer, President and Director | 60 | 130.38万美元 | 未持股 | 2023-06-20 |
| John K.A. Prendergast | 男 | Director, Chairman of the Board | 69 | 21.29万美元 | 未持股 | 2023-06-20 |
| Robert K. deVeer, Jr. | 男 | Director | 77 | 15.50万美元 | 未持股 | 2023-06-20 |
| J. Stanley Hull | 男 | Director | 70 | 14.50万美元 | 未持股 | 2023-06-20 |
| Arlene M. Morris | 女 | Director | 71 | 14.00万美元 | 未持股 | 2023-06-20 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Carl Spana | 男 | Chief Executive Officer, President and Director | 60 | 130.38万美元 | 未持股 | 2023-06-20 |
| Stephen T. Wills | 男 | Chief Financial Officer, Chief Operating Officer, Executive Vice President, Secretary and Treasurer | 66 | 119.32万美元 | 未持股 | 2023-06-20 |
董事简历
中英对照 | 中文 | 英文- Anthony M. Manning
-
AnthonyM.Manning自2017年9月起担任Palatin的董事。自2013年以来，曼宁博士一直担任MomentaPharmaceuticals，Inc.的研究高级副总裁，并自2018年以来担任首席科学官，该公司是一家公开上市的生物制药公司，致力于开发针对罕见免疫相关疾病的创新疗法。从2011年到2013年，他是AileronTherapeutics，Inc.（一家公开上市的生物制药公司，开发用于癌症和其他疾病的吻合肽疗法）研究与开发的高级副总裁。从2007年到2011年，他担任Biogen，Inc.（一家公开上市的生物制药公司，开发用于神经系统和神经退行性疾病的药物）的Vice President和炎症和自身免疫性疾病研究主管。从2002年到2007年，他曾担任Roche Pharmaceuticals公司（Roche Holding AG的制药部门）的炎症、自身免疫和移植研究的Vice President兼全球治疗领域主管，从2000年到2002年，他曾担任Pharmacia公司（一个全球性制药公司，于2002年被辉瑞公司收购）的Vice President。Manning博士获得了他的博士学位，硕士学位。和B.SC.来自新西兰达尼丁的奥塔哥大学。
Anthony M. Manning,has been a director of Palatin since September 2017. Since March 2021, Dr. Manning has been providing scientific and strategic advice to biotechnology companies as the principal of Manning Bio Worldwide LLC. From 2013 until March 2021, Dr. Manning was senior vice president of research, and since 2018 was chief scientific officer, at Momenta Pharmaceuticals, Inc., a publicly traded biopharmaceutical company developing innovative therapeutics for rare immune-related diseases which was acquired by Johnson & Johnson in October 2020. From 2011 to 2013, he was senior vice president of research and development at Aileron Therapeutics, Inc., a publicly traded biopharmaceutical company developing stapled peptide therapeutics for cancers and other diseases. From 2007 to 2011, he was vice president and head of inflammation and autoimmune diseases research at Biogen, Inc., a publicly traded biopharmaceutical company developing medicines for neurological and neurodegenerative conditions. From 2002 to 2007, he was vice president and global therapy area head for Inflammation, Autoimmunity and Transplantation Research at Roche Pharmaceuticals, the pharmaceutical division of Roche Holding AG, and from 2000 to 2002 he was vice president of Pharmacia, a global pharmaceutical company acquired by Pfizer in 2002. Dr. Manning received his Ph.D., M.Sc. and B.Sc. from the University of Otago, Dunedin, New Zealand. - AnthonyM.Manning自2017年9月起担任Palatin的董事。自2013年以来，曼宁博士一直担任MomentaPharmaceuticals，Inc.的研究高级副总裁，并自2018年以来担任首席科学官，该公司是一家公开上市的生物制药公司，致力于开发针对罕见免疫相关疾病的创新疗法。从2011年到2013年，他是AileronTherapeutics，Inc.（一家公开上市的生物制药公司，开发用于癌症和其他疾病的吻合肽疗法）研究与开发的高级副总裁。从2007年到2011年，他担任Biogen，Inc.（一家公开上市的生物制药公司，开发用于神经系统和神经退行性疾病的药物）的Vice President和炎症和自身免疫性疾病研究主管。从2002年到2007年，他曾担任Roche Pharmaceuticals公司（Roche Holding AG的制药部门）的炎症、自身免疫和移植研究的Vice President兼全球治疗领域主管，从2000年到2002年，他曾担任Pharmacia公司（一个全球性制药公司，于2002年被辉瑞公司收购）的Vice President。Manning博士获得了他的博士学位，硕士学位。和B.SC.来自新西兰达尼丁的奥塔哥大学。
- Anthony M. Manning,has been a director of Palatin since September 2017. Since March 2021, Dr. Manning has been providing scientific and strategic advice to biotechnology companies as the principal of Manning Bio Worldwide LLC. From 2013 until March 2021, Dr. Manning was senior vice president of research, and since 2018 was chief scientific officer, at Momenta Pharmaceuticals, Inc., a publicly traded biopharmaceutical company developing innovative therapeutics for rare immune-related diseases which was acquired by Johnson & Johnson in October 2020. From 2011 to 2013, he was senior vice president of research and development at Aileron Therapeutics, Inc., a publicly traded biopharmaceutical company developing stapled peptide therapeutics for cancers and other diseases. From 2007 to 2011, he was vice president and head of inflammation and autoimmune diseases research at Biogen, Inc., a publicly traded biopharmaceutical company developing medicines for neurological and neurodegenerative conditions. From 2002 to 2007, he was vice president and global therapy area head for Inflammation, Autoimmunity and Transplantation Research at Roche Pharmaceuticals, the pharmaceutical division of Roche Holding AG, and from 2000 to 2002 he was vice president of Pharmacia, a global pharmaceutical company acquired by Pfizer in 2002. Dr. Manning received his Ph.D., M.Sc. and B.Sc. from the University of Otago, Dunedin, New Zealand.
- Alan W. Dunton
-
Alan W. Dunton，药学博士，自2006年10月起担任董事会成员，自2006年4月起担任咨询公司Danerius有限公司负责人，2007年1月到2009年3月，Dunton博士在Panacos Pharmaceuticals公司担任总裁兼首席执行官；2009年3月至2011年1月担任Panacos常务董事。Dunton博士是上市公司Oragenics和Palatin Technologies的董事会成员。在过去的5年里，他曾是被Reckitt Benckiser Group plc收购的上市公司Adams Respiratory Therapeutics、 MediciNova, Inc.以及前上市公司Panacos Pharmaceuticals，Inc. 的董事会成员。另外，他还曾是EpiCept公司董事长，2013年他将EpiCept公司与Immune Pharmaceuticals合并。目前他还是私人医药公司Sancilio & Company的董事。
Alan W. Dunton,has been a director of Palatin since June 2011. He founded Danerius, LLC, a biotechnology consulting company, in 2006. From November 2015 through March 2018, he was senior vice president of research, development, and regulatory affairs for Purdue Pharma L.P., with responsibilities for overall research strategy and development programs. From January 2007 to March 2009, Dr. Dunton served as president and chief executive officer of Panacos Pharmaceuticals Inc. and he served as a managing director of Panacos from March 2009 to January 2011. Dr. Dunton is currently a member of the board of directors of the publicly traded companies Recce Pharmaceuticals Ltd (ASX: RCE), CorMedix Inc. (NYSE: CRMD) and Oragenics, Inc. (NYSE: OGEN). He previously served on the board of directors of the publicly traded companies Targacept, Inc., EpiCept Corporation (as Non-Executive Chairman), Adams Respiratory Therapeutics, Inc. (acquired by Reckitt Benckiser Group plc), MediciNova, Inc. and Panacos Pharmaceuticals, Inc. Dr. Dunton has served as a director or executive officer of various pharmaceutical companies, and from 1994 to 2001, Dr. Dunton was a senior executive in various capacities in the Pharmaceuticals Group of Johnson & Johnson, including president and managing director of the Janssen Research Foundation, the primary global R&D organization for Johnson & Johnson. Dr. Dunton received his M.D. degree from New York University School of Medicine, where he completed his residency in internal medicine. He also was a Fellow in Clinical Pharmacology at the New York Hospital/Cornell University Medical Center. - Alan W. Dunton，药学博士，自2006年10月起担任董事会成员，自2006年4月起担任咨询公司Danerius有限公司负责人，2007年1月到2009年3月，Dunton博士在Panacos Pharmaceuticals公司担任总裁兼首席执行官；2009年3月至2011年1月担任Panacos常务董事。Dunton博士是上市公司Oragenics和Palatin Technologies的董事会成员。在过去的5年里，他曾是被Reckitt Benckiser Group plc收购的上市公司Adams Respiratory Therapeutics、 MediciNova, Inc.以及前上市公司Panacos Pharmaceuticals，Inc. 的董事会成员。另外，他还曾是EpiCept公司董事长，2013年他将EpiCept公司与Immune Pharmaceuticals合并。目前他还是私人医药公司Sancilio & Company的董事。
- Alan W. Dunton,has been a director of Palatin since June 2011. He founded Danerius, LLC, a biotechnology consulting company, in 2006. From November 2015 through March 2018, he was senior vice president of research, development, and regulatory affairs for Purdue Pharma L.P., with responsibilities for overall research strategy and development programs. From January 2007 to March 2009, Dr. Dunton served as president and chief executive officer of Panacos Pharmaceuticals Inc. and he served as a managing director of Panacos from March 2009 to January 2011. Dr. Dunton is currently a member of the board of directors of the publicly traded companies Recce Pharmaceuticals Ltd (ASX: RCE), CorMedix Inc. (NYSE: CRMD) and Oragenics, Inc. (NYSE: OGEN). He previously served on the board of directors of the publicly traded companies Targacept, Inc., EpiCept Corporation (as Non-Executive Chairman), Adams Respiratory Therapeutics, Inc. (acquired by Reckitt Benckiser Group plc), MediciNova, Inc. and Panacos Pharmaceuticals, Inc. Dr. Dunton has served as a director or executive officer of various pharmaceutical companies, and from 1994 to 2001, Dr. Dunton was a senior executive in various capacities in the Pharmaceuticals Group of Johnson & Johnson, including president and managing director of the Janssen Research Foundation, the primary global R&D organization for Johnson & Johnson. Dr. Dunton received his M.D. degree from New York University School of Medicine, where he completed his residency in internal medicine. He also was a Fellow in Clinical Pharmacology at the New York Hospital/Cornell University Medical Center.
- Carl Spana
-
Carl Spana, Palatin的联合创始人，曾任职Palatin Technologies, Inc.。2000年6月14日起担任首席执行官兼总裁。1996年6月以来，他一直担任Palatin的董事；1995年7月以来，他一直担任Palatin Technologies, Inc.全资子公司RhoMed Incorporated的董事。从1996年6月到2000年6月14日，他担任公司的执行副总裁和Palatin Technologies, Inc.的首席技术官。从1993年6月到1996年6月，他担任派拉蒙资本投资有限责任公司（生物技术和生物制药商业银行公司）和The Castle Group有限公司（医疗风险投资公司）的副总裁。通过他在Paramount Capital Investments, LLC和Castle Group Ltd.的工作，他共同创立并收购了几家私人生物技术公司。1991年7月至1993年6月，他是百时美施贵宝（Bristol-Myers Squibb，一家上市制药公司）的研究助理，在那里他参与免疫学领域的科学研究。他持有The Johns Hopkins University的分子生物学博士学位和Rutgers University的生物化学学士学位。
Carl Spana,co-founder of Palatin, has been Palatin Technologies, Inc. Chief Executive Officer and President since June 14, 2000. He has been a director of Palatin since June 1996 and has been a director of Palatin Technologies, Inc. wholly owned subsidiary, RhoMed Incorporated, since July 1995. From June 1996 through June 14, 2000, Dr. Spana served as an executive vice president of the Company and Palatin Technologies, Inc. chief technical officer. From June 1993 to June 1996, Dr. Spana was vice president of Paramount Capital Investments, LLC, a biotechnology and biopharmaceutical merchant banking firm, and of The Castle Group Ltd., a medical venture capital firm. Through his work at Paramount Capital Investments and The Castle Group, Dr. Spana co-founded and acquired several private biotechnology firms. From July 1991 to June 1993, Dr. Spana was a Research Associate at Bristol-Myers Squibb, a publicly held pharmaceutical company, where he was involved in scientific research in the field of immunology. Dr. Spana received his Ph.D. in molecular biology from The Johns Hopkins University and his B.S. in biochemistry from Rutgers University. - Carl Spana, Palatin的联合创始人，曾任职Palatin Technologies, Inc.。2000年6月14日起担任首席执行官兼总裁。1996年6月以来，他一直担任Palatin的董事；1995年7月以来，他一直担任Palatin Technologies, Inc.全资子公司RhoMed Incorporated的董事。从1996年6月到2000年6月14日，他担任公司的执行副总裁和Palatin Technologies, Inc.的首席技术官。从1993年6月到1996年6月，他担任派拉蒙资本投资有限责任公司（生物技术和生物制药商业银行公司）和The Castle Group有限公司（医疗风险投资公司）的副总裁。通过他在Paramount Capital Investments, LLC和Castle Group Ltd.的工作，他共同创立并收购了几家私人生物技术公司。1991年7月至1993年6月，他是百时美施贵宝（Bristol-Myers Squibb，一家上市制药公司）的研究助理，在那里他参与免疫学领域的科学研究。他持有The Johns Hopkins University的分子生物学博士学位和Rutgers University的生物化学学士学位。
- Carl Spana,co-founder of Palatin, has been Palatin Technologies, Inc. Chief Executive Officer and President since June 14, 2000. He has been a director of Palatin since June 1996 and has been a director of Palatin Technologies, Inc. wholly owned subsidiary, RhoMed Incorporated, since July 1995. From June 1996 through June 14, 2000, Dr. Spana served as an executive vice president of the Company and Palatin Technologies, Inc. chief technical officer. From June 1993 to June 1996, Dr. Spana was vice president of Paramount Capital Investments, LLC, a biotechnology and biopharmaceutical merchant banking firm, and of The Castle Group Ltd., a medical venture capital firm. Through his work at Paramount Capital Investments and The Castle Group, Dr. Spana co-founded and acquired several private biotechnology firms. From July 1991 to June 1993, Dr. Spana was a Research Associate at Bristol-Myers Squibb, a publicly held pharmaceutical company, where he was involved in scientific research in the field of immunology. Dr. Spana received his Ph.D. in molecular biology from The Johns Hopkins University and his B.S. in biochemistry from Rutgers University.
- John K.A. Prendergast
-
John K.A. Prendergast，是Palatin的共同创始人；2000年6月14日起，担任董事长；1996年8月起，担任董事。他从1993年起，就是Summercloud Bay的总裁、唯一股东，这是服务于生物技术行业的独立咨询公司。他现为Antyra的董事、执行董事长，这是私营的生物制药公司。之前，他曾担任一些生物生命科学公司的董事：AVAX Technologies, Inc.、Avigen, Inc. 和 MediciNova, Inc.1991年10月至1997年12月，他是The Castle Group的总经理，这是一个医疗行业风投公司。他获得了的澳大利亚悉尼University of New South Wales的硕士、博士学位，以及Harvard University的管理学C.S.S。
John K.A. Prendergast,has served as the non-executive Chairman of the board since June 14, 2000, and as a director since August 1996. While Dr. Prendergast has served as a member of the board, he does not serve, and has not served, in a management or operational role with the Company. Dr. Prendergast has been president and sole stockholder of Summercloud Bay, Inc., an independent consulting firm providing services to the biotechnology industry, since 1993. Dr. Prendergast is lead director of Nighthawk Biosciences, Inc. (NYSE American: NHWK), a publicly traded clinical stage immunotherapy company, and a director and Executive Chairman of Recce Pharmaceuticals Ltd. (ASX: RCE), a publicly traded Australian pharmaceutical company developing a new class of anti-infective agents. He was previously a member of the board of the life science companies AVAX Technologies, Inc., Avigen, Inc. and MediciNova, Inc. From October 1991 through December 1997, Dr. Prendergast was a managing director of The Castle Group Ltd., a medical venture capital firm. Dr. Prendergast received his M.Sc. and Ph.D. from the University of New South Wales, Sydney, Australia and a C.S.S. in administration and management from Harvard University. - John K.A. Prendergast，是Palatin的共同创始人；2000年6月14日起，担任董事长；1996年8月起，担任董事。他从1993年起，就是Summercloud Bay的总裁、唯一股东，这是服务于生物技术行业的独立咨询公司。他现为Antyra的董事、执行董事长，这是私营的生物制药公司。之前，他曾担任一些生物生命科学公司的董事：AVAX Technologies, Inc.、Avigen, Inc. 和 MediciNova, Inc.1991年10月至1997年12月，他是The Castle Group的总经理，这是一个医疗行业风投公司。他获得了的澳大利亚悉尼University of New South Wales的硕士、博士学位，以及Harvard University的管理学C.S.S。
- John K.A. Prendergast,has served as the non-executive Chairman of the board since June 14, 2000, and as a director since August 1996. While Dr. Prendergast has served as a member of the board, he does not serve, and has not served, in a management or operational role with the Company. Dr. Prendergast has been president and sole stockholder of Summercloud Bay, Inc., an independent consulting firm providing services to the biotechnology industry, since 1993. Dr. Prendergast is lead director of Nighthawk Biosciences, Inc. (NYSE American: NHWK), a publicly traded clinical stage immunotherapy company, and a director and Executive Chairman of Recce Pharmaceuticals Ltd. (ASX: RCE), a publicly traded Australian pharmaceutical company developing a new class of anti-infective agents. He was previously a member of the board of the life science companies AVAX Technologies, Inc., Avigen, Inc. and MediciNova, Inc. From October 1991 through December 1997, Dr. Prendergast was a managing director of The Castle Group Ltd., a medical venture capital firm. Dr. Prendergast received his M.Sc. and Ph.D. from the University of New South Wales, Sydney, Australia and a C.S.S. in administration and management from Harvard University.
- Robert K. deVeer, Jr.
-
Robert K. deVeer, Jr.，1998年1月起担任董事。他一直是私营投资公司deVeer Capital LLC的总裁。他曾担任Solutia的董事，这是一个化学品材料上市公司，直到2012年7月它与Eastman Chemical Company合并。1995年到1996年退休，他在纽约的Lehman Brothers担任的总经理、工业部门总监。1973-1995，他在纽约的CS First Boston担任了愈益重要的多个职务，包括：项目融资总监、工业部总监、自然资源部总监。他曾担任First Boston Foundation的总经理、投资银行委员会成员、受托人。他获得了Yale University的经济学士学位、Stanford Graduate School of Business金融方向的工商管理硕士学位。
Robert K. deVeer, Jr.,has been a director of Palatin since November 1998. Since January 1997, Mr. deVeer has been the president of deVeer Capital LLC, a private investment company. He was a director of Solutia Inc., a publicly held chemical-based materials company, until its merger with Eastman Chemical Company in July 2012. From 1995 until his retirement in 1996, Mr. deVeer served as Managing Director, Head of Industrial Group, at New York-based Lehman Brothers. From 1973 to 1995, he held increasingly responsible positions at New York-based CS First Boston, including Head of Project Finance, Head of Industrials and Head of Natural Resources. He was a managing director, member of the investment banking committee and a trustee of the First Boston Foundation. He received a B.A. in economics from Yale University and an M.B.A. in finance from Stanford Graduate School of Business. - Robert K. deVeer, Jr.，1998年1月起担任董事。他一直是私营投资公司deVeer Capital LLC的总裁。他曾担任Solutia的董事，这是一个化学品材料上市公司，直到2012年7月它与Eastman Chemical Company合并。1995年到1996年退休，他在纽约的Lehman Brothers担任的总经理、工业部门总监。1973-1995，他在纽约的CS First Boston担任了愈益重要的多个职务，包括：项目融资总监、工业部总监、自然资源部总监。他曾担任First Boston Foundation的总经理、投资银行委员会成员、受托人。他获得了Yale University的经济学士学位、Stanford Graduate School of Business金融方向的工商管理硕士学位。
- Robert K. deVeer, Jr.,has been a director of Palatin since November 1998. Since January 1997, Mr. deVeer has been the president of deVeer Capital LLC, a private investment company. He was a director of Solutia Inc., a publicly held chemical-based materials company, until its merger with Eastman Chemical Company in July 2012. From 1995 until his retirement in 1996, Mr. deVeer served as Managing Director, Head of Industrial Group, at New York-based Lehman Brothers. From 1973 to 1995, he held increasingly responsible positions at New York-based CS First Boston, including Head of Project Finance, Head of Industrials and Head of Natural Resources. He was a managing director, member of the investment banking committee and a trustee of the First Boston Foundation. He received a B.A. in economics from Yale University and an M.B.A. in finance from Stanford Graduate School of Business.
- J. Stanley Hull
-
J. Stanley Hull，2005年9月起担任董事。他在销售和营销方面，有着30多年的经验。他在1987年10月加入Glaxo Smith Kline，这是一个研究型制药公司；于2010年5月退休，时任药物高级副总裁；此前，曾在该公司的研发机构工作，担任过副总裁、神经病与精神病疗法开发及产品策略全球总监。此前，他是Glaxo Wellcome感染性疾病和肠胃病 部门的营销副总裁。他在1978年进入制药行业，任职于SmithKline and French Laboratories。他获得了University of North Carolina at Greensboro的工商管理学士学位。
J. Stanley Hull,has been a director of Palatin since September 2005. Mr. Hull has over three decades of experience in the field of sales, marketing, and drug development. Mr. Hull joined GlaxoSmithKline, a research-based pharmaceutical company, in October 1987 and retired as Senior Vice President, Pharmaceuticals – North America in May 2010. Mr. Hull was responsible for all commercial activities including sales, marketing, sales training, and office operations. Previously, Mr. Hull served in the R&D organization of Glaxo Wellcome as Vice President and Worldwide Director of Therapeutic Development and Product Strategy – Neurology and Psychiatry. Prior to his service in the R&D organization he was Vice President of Marketing – Infectious Diseases and Gastroenterology for Glaxo Wellcome-U.S. Mr. Hull started his career in the pharmaceutical industry with SmithKline and French Laboratories in 1978. Mr. Hull received his B.S. in business administration from the University of North Carolina at Greensboro. - J. Stanley Hull，2005年9月起担任董事。他在销售和营销方面，有着30多年的经验。他在1987年10月加入Glaxo Smith Kline，这是一个研究型制药公司；于2010年5月退休，时任药物高级副总裁；此前，曾在该公司的研发机构工作，担任过副总裁、神经病与精神病疗法开发及产品策略全球总监。此前，他是Glaxo Wellcome感染性疾病和肠胃病 部门的营销副总裁。他在1978年进入制药行业，任职于SmithKline and French Laboratories。他获得了University of North Carolina at Greensboro的工商管理学士学位。
- J. Stanley Hull,has been a director of Palatin since September 2005. Mr. Hull has over three decades of experience in the field of sales, marketing, and drug development. Mr. Hull joined GlaxoSmithKline, a research-based pharmaceutical company, in October 1987 and retired as Senior Vice President, Pharmaceuticals – North America in May 2010. Mr. Hull was responsible for all commercial activities including sales, marketing, sales training, and office operations. Previously, Mr. Hull served in the R&D organization of Glaxo Wellcome as Vice President and Worldwide Director of Therapeutic Development and Product Strategy – Neurology and Psychiatry. Prior to his service in the R&D organization he was Vice President of Marketing – Infectious Diseases and Gastroenterology for Glaxo Wellcome-U.S. Mr. Hull started his career in the pharmaceutical industry with SmithKline and French Laboratories in 1978. Mr. Hull received his B.S. in business administration from the University of North Carolina at Greensboro.
- Arlene M. Morris
-
Arlene M. Morris，她一直担任Palatin的董事（2015年6月以来）。自2015年5月起，她担任Willow Advisors, LLC（生物技术公司的业务发展、商业发展和企业战略咨询公司）的首席执行官。2012年4月至2015年5月，她担任Syndax Pharmaceuticals, Inc.（一家私营生物制药公司，专注于治疗耐药癌症的表观遗传疗法的开发和商业化）的总裁兼首席执行官，并于2011年5月至2015年5月担任董事会成员。2003年至2011年1月，她担任Affymax, Inc.（上市的生物技术公司）的总裁、首席执行官和董事会成员。她还曾在Clearview Projects, Inc.（企业咨询公司）、Coulter Pharmaceutical, Inc.（公开上市的制药公司）、Scios Inc.（公开上市的生物制药公司）和Johnson & Johnson（公开上市的医疗保健公司）担任各种管理和执行职位。她目前是Viridian Therapeutics, Inc.（公开交易的治疗抗体公司）和Cogent Biosciences, Inc.（公开交易的肿瘤生物制药公司）的董事会成员，并曾担任Viveve Medical, Inc.（公开交易的女性医疗保健医疗设备公司）的董事，直到2023年2月，Neovacs SA（公开交易的法国公司），Biodel Inc.（公开交易的专业制药公司）。从2015年到2016年与Albireo Limited和Dimension Therapeutics, Inc.（上市的基因治疗公司）合并，直到2017年被Ultragenyx Pharmaceutical Inc.收购。她持有Carlow College的生物和化学学士学位。
Arlene M. Morris,has been a director of Palatin since June 2015. Since May 2015 she has served as the chief executive officer of Willow Advisors, LLC, a consultancy to biotech companies on business development, commercial development and corporate strategy. From April 2012 until May 2015, she was President and Chief Executive Officer of Syndax Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on the development and commercialization of an epigenetic therapy for treatment-resistant cancers, and was a member of the board of directors from May 2011 until May 2015. From 2003 to January 2011, Ms. Morris served as the President, Chief Executive Officer and a member of the board of directors of Affymax, Inc., a publicly traded biotechnology company. Ms. Morris has also held various management and executive positions at Clearview Projects, Inc., a corporate advisory firm, Coulter Pharmaceutical, Inc., a publicly traded pharmaceutical company, Scios Inc., a publicly traded biopharmaceutical company, and Johnson & Johnson, a publicly traded healthcare company. She is currently a member of the board of directors Viridian Therapeutics, Inc. (NASDAQ: VRDN), a publicly traded therapeutic antibody company, and Cogent Biosciences, Inc. (NASDAQ: COGT), a publicly traded oncology biopharmaceutical company, is a director (since February 2022) and currently chair of TC Biopharm (Holdings) PLC (Nasdaq: TCBP), a United Kingdom biopharmaceutical company, and was previously a director of Viveve Medical, Inc., a publicly traded female healthcare medical device company, until February 2023, Neovacs SA, a publicly traded French company, Biodel Inc., a publicly traded specialty pharmaceutical company, from 2015 until its merger with Albireo Limited in 2016, and Dimension Therapeutics, Inc., a publicly traded gene therapy company, until its acquisition by Ultragenyx Pharmaceutical Inc. in 2017. Ms. Morris received a B.A. in Biology and Chemistry from Carlow College. - Arlene M. Morris，她一直担任Palatin的董事（2015年6月以来）。自2015年5月起，她担任Willow Advisors, LLC（生物技术公司的业务发展、商业发展和企业战略咨询公司）的首席执行官。2012年4月至2015年5月，她担任Syndax Pharmaceuticals, Inc.（一家私营生物制药公司，专注于治疗耐药癌症的表观遗传疗法的开发和商业化）的总裁兼首席执行官，并于2011年5月至2015年5月担任董事会成员。2003年至2011年1月，她担任Affymax, Inc.（上市的生物技术公司）的总裁、首席执行官和董事会成员。她还曾在Clearview Projects, Inc.（企业咨询公司）、Coulter Pharmaceutical, Inc.（公开上市的制药公司）、Scios Inc.（公开上市的生物制药公司）和Johnson & Johnson（公开上市的医疗保健公司）担任各种管理和执行职位。她目前是Viridian Therapeutics, Inc.（公开交易的治疗抗体公司）和Cogent Biosciences, Inc.（公开交易的肿瘤生物制药公司）的董事会成员，并曾担任Viveve Medical, Inc.（公开交易的女性医疗保健医疗设备公司）的董事，直到2023年2月，Neovacs SA（公开交易的法国公司），Biodel Inc.（公开交易的专业制药公司）。从2015年到2016年与Albireo Limited和Dimension Therapeutics, Inc.（上市的基因治疗公司）合并，直到2017年被Ultragenyx Pharmaceutical Inc.收购。她持有Carlow College的生物和化学学士学位。
- Arlene M. Morris,has been a director of Palatin since June 2015. Since May 2015 she has served as the chief executive officer of Willow Advisors, LLC, a consultancy to biotech companies on business development, commercial development and corporate strategy. From April 2012 until May 2015, she was President and Chief Executive Officer of Syndax Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on the development and commercialization of an epigenetic therapy for treatment-resistant cancers, and was a member of the board of directors from May 2011 until May 2015. From 2003 to January 2011, Ms. Morris served as the President, Chief Executive Officer and a member of the board of directors of Affymax, Inc., a publicly traded biotechnology company. Ms. Morris has also held various management and executive positions at Clearview Projects, Inc., a corporate advisory firm, Coulter Pharmaceutical, Inc., a publicly traded pharmaceutical company, Scios Inc., a publicly traded biopharmaceutical company, and Johnson & Johnson, a publicly traded healthcare company. She is currently a member of the board of directors Viridian Therapeutics, Inc. (NASDAQ: VRDN), a publicly traded therapeutic antibody company, and Cogent Biosciences, Inc. (NASDAQ: COGT), a publicly traded oncology biopharmaceutical company, is a director (since February 2022) and currently chair of TC Biopharm (Holdings) PLC (Nasdaq: TCBP), a United Kingdom biopharmaceutical company, and was previously a director of Viveve Medical, Inc., a publicly traded female healthcare medical device company, until February 2023, Neovacs SA, a publicly traded French company, Biodel Inc., a publicly traded specialty pharmaceutical company, from 2015 until its merger with Albireo Limited in 2016, and Dimension Therapeutics, Inc., a publicly traded gene therapy company, until its acquisition by Ultragenyx Pharmaceutical Inc. in 2017. Ms. Morris received a B.A. in Biology and Chemistry from Carlow College.
高管简历
中英对照 | 中文 | 英文- Carl Spana
Carl Spana, Palatin的联合创始人，曾任职Palatin Technologies, Inc.。2000年6月14日起担任首席执行官兼总裁。1996年6月以来，他一直担任Palatin的董事；1995年7月以来，他一直担任Palatin Technologies, Inc.全资子公司RhoMed Incorporated的董事。从1996年6月到2000年6月14日，他担任公司的执行副总裁和Palatin Technologies, Inc.的首席技术官。从1993年6月到1996年6月，他担任派拉蒙资本投资有限责任公司（生物技术和生物制药商业银行公司）和The Castle Group有限公司（医疗风险投资公司）的副总裁。通过他在Paramount Capital Investments, LLC和Castle Group Ltd.的工作，他共同创立并收购了几家私人生物技术公司。1991年7月至1993年6月，他是百时美施贵宝（Bristol-Myers Squibb，一家上市制药公司）的研究助理，在那里他参与免疫学领域的科学研究。他持有The Johns Hopkins University的分子生物学博士学位和Rutgers University的生物化学学士学位。
Carl Spana,co-founder of Palatin, has been Palatin Technologies, Inc. Chief Executive Officer and President since June 14, 2000. He has been a director of Palatin since June 1996 and has been a director of Palatin Technologies, Inc. wholly owned subsidiary, RhoMed Incorporated, since July 1995. From June 1996 through June 14, 2000, Dr. Spana served as an executive vice president of the Company and Palatin Technologies, Inc. chief technical officer. From June 1993 to June 1996, Dr. Spana was vice president of Paramount Capital Investments, LLC, a biotechnology and biopharmaceutical merchant banking firm, and of The Castle Group Ltd., a medical venture capital firm. Through his work at Paramount Capital Investments and The Castle Group, Dr. Spana co-founded and acquired several private biotechnology firms. From July 1991 to June 1993, Dr. Spana was a Research Associate at Bristol-Myers Squibb, a publicly held pharmaceutical company, where he was involved in scientific research in the field of immunology. Dr. Spana received his Ph.D. in molecular biology from The Johns Hopkins University and his B.S. in biochemistry from Rutgers University.- Carl Spana, Palatin的联合创始人，曾任职Palatin Technologies, Inc.。2000年6月14日起担任首席执行官兼总裁。1996年6月以来，他一直担任Palatin的董事；1995年7月以来，他一直担任Palatin Technologies, Inc.全资子公司RhoMed Incorporated的董事。从1996年6月到2000年6月14日，他担任公司的执行副总裁和Palatin Technologies, Inc.的首席技术官。从1993年6月到1996年6月，他担任派拉蒙资本投资有限责任公司（生物技术和生物制药商业银行公司）和The Castle Group有限公司（医疗风险投资公司）的副总裁。通过他在Paramount Capital Investments, LLC和Castle Group Ltd.的工作，他共同创立并收购了几家私人生物技术公司。1991年7月至1993年6月，他是百时美施贵宝（Bristol-Myers Squibb，一家上市制药公司）的研究助理，在那里他参与免疫学领域的科学研究。他持有The Johns Hopkins University的分子生物学博士学位和Rutgers University的生物化学学士学位。
- Carl Spana,co-founder of Palatin, has been Palatin Technologies, Inc. Chief Executive Officer and President since June 14, 2000. He has been a director of Palatin since June 1996 and has been a director of Palatin Technologies, Inc. wholly owned subsidiary, RhoMed Incorporated, since July 1995. From June 1996 through June 14, 2000, Dr. Spana served as an executive vice president of the Company and Palatin Technologies, Inc. chief technical officer. From June 1993 to June 1996, Dr. Spana was vice president of Paramount Capital Investments, LLC, a biotechnology and biopharmaceutical merchant banking firm, and of The Castle Group Ltd., a medical venture capital firm. Through his work at Paramount Capital Investments and The Castle Group, Dr. Spana co-founded and acquired several private biotechnology firms. From July 1991 to June 1993, Dr. Spana was a Research Associate at Bristol-Myers Squibb, a publicly held pharmaceutical company, where he was involved in scientific research in the field of immunology. Dr. Spana received his Ph.D. in molecular biology from The Johns Hopkins University and his B.S. in biochemistry from Rutgers University.
- Stephen T. Wills
Stephen T. Wills，1997年起，担任副总裁、秘书、财务总管、首席财务官；2005年起，担任运营执行副总裁，直到2011年6月被任命为首席运营官、执行副总裁。1997年7月至2000年8月，他还是Derma Sciences的副总裁、首席财务官，这是一个供应伤口、皮肤护理产品的上市公司，目前担任其首席董事。之前，他曾担任Miami International Securities Exchange, LLC的董事、审核委员会主席，这是私营的全电子化的期权和股票交易所，目前仍在开发中；此前，他曾担任上市公司U.S. Helicopter Corp.的董事。1991年至2000年8月，他是Golomb, Wills & Company, P.C。的总裁、首席运营官，这是一个公共会计公司。他是注册会计师，获得West Chester University的会计学士学位、Temple University的税务硕士学位。
Stephen T. Wills,currently serves as the Chief Financial Officer (since 1997), Chief Operating Officer (since 2011), Treasurer and Secretary, of Palatin. Mr. Wills has served on the board of directors of MediWound Ltd. (Nasdaq: MDWD), a biopharmaceutical company focused on treatment in the fields of severe burns, chronic and other hard to heal wounds, since April 2017, and as Chairman from October 2017 until August 2022, and starting September 2022, is the chairman of the audit committee and a member of the compensation committee. He also has served on the board of directors of Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, since March 2019, and is chairman of the audit committee and a member of the compensation and finance committees. Mr. Wills serves as the Chief Financial Officer of Cactus Acquisition Corp (Nasdaq: CCTS), a Special Purpose Acquisition Company (SPAC). Mr. Wills served on the board of directors of Amryt Pharma Plc, a biopharmaceutical company focused on developing and delivering treatments to help improve the lives of patients with rare and orphan diseases, from September 2019 through April 2023, when Amryt was acquired by Chiesi Farmaceutici. Mr. Wills served on the board of trustees and executive committee of The Hun School of Princeton, a college preparatory day and boarding school since 2014, and as its Chairman starting June 2018, to his retirement in June 2023. Mr. Wills served on the board of directors of Caliper Corporation, a psychological assessment and talent development company, since March 2016, and as Chairman from December 2016 to December 2019, when PSI Corporation acquired Caliper. Mr. Wills served as Executive Chairman and Interim Principal Executive Officer of Derma Sciences, Inc., a provider of advanced wound care products, from December 2015 to February 2017, when Derma Sciences was acquired by Integra Lifesciences (Nasdaq: IART). Previously, Mr. Wills served on the board of directors of Derma Sciences as the lead director and chairperson of the audit committee from June 2000 to December 2015, and served as the Chief Financial Officer of Derma Sciences from 1997 to 2000. Mr. Wills served as the President and Chief Operating Officer of Wills, Owens & Baker, P.C., a public accounting firm, from 1991 to 2000. Mr. Wills, a certified public accountant, earned his Bachelor of Science in accounting from West Chester University, and a Master of Science in taxation from Temple University.- Stephen T. Wills，1997年起，担任副总裁、秘书、财务总管、首席财务官；2005年起，担任运营执行副总裁，直到2011年6月被任命为首席运营官、执行副总裁。1997年7月至2000年8月，他还是Derma Sciences的副总裁、首席财务官，这是一个供应伤口、皮肤护理产品的上市公司，目前担任其首席董事。之前，他曾担任Miami International Securities Exchange, LLC的董事、审核委员会主席，这是私营的全电子化的期权和股票交易所，目前仍在开发中；此前，他曾担任上市公司U.S. Helicopter Corp.的董事。1991年至2000年8月，他是Golomb, Wills & Company, P.C。的总裁、首席运营官，这是一个公共会计公司。他是注册会计师，获得West Chester University的会计学士学位、Temple University的税务硕士学位。
- Stephen T. Wills,currently serves as the Chief Financial Officer (since 1997), Chief Operating Officer (since 2011), Treasurer and Secretary, of Palatin. Mr. Wills has served on the board of directors of MediWound Ltd. (Nasdaq: MDWD), a biopharmaceutical company focused on treatment in the fields of severe burns, chronic and other hard to heal wounds, since April 2017, and as Chairman from October 2017 until August 2022, and starting September 2022, is the chairman of the audit committee and a member of the compensation committee. He also has served on the board of directors of Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, since March 2019, and is chairman of the audit committee and a member of the compensation and finance committees. Mr. Wills serves as the Chief Financial Officer of Cactus Acquisition Corp (Nasdaq: CCTS), a Special Purpose Acquisition Company (SPAC). Mr. Wills served on the board of directors of Amryt Pharma Plc, a biopharmaceutical company focused on developing and delivering treatments to help improve the lives of patients with rare and orphan diseases, from September 2019 through April 2023, when Amryt was acquired by Chiesi Farmaceutici. Mr. Wills served on the board of trustees and executive committee of The Hun School of Princeton, a college preparatory day and boarding school since 2014, and as its Chairman starting June 2018, to his retirement in June 2023. Mr. Wills served on the board of directors of Caliper Corporation, a psychological assessment and talent development company, since March 2016, and as Chairman from December 2016 to December 2019, when PSI Corporation acquired Caliper. Mr. Wills served as Executive Chairman and Interim Principal Executive Officer of Derma Sciences, Inc., a provider of advanced wound care products, from December 2015 to February 2017, when Derma Sciences was acquired by Integra Lifesciences (Nasdaq: IART). Previously, Mr. Wills served on the board of directors of Derma Sciences as the lead director and chairperson of the audit committee from June 2000 to December 2015, and served as the Chief Financial Officer of Derma Sciences from 1997 to 2000. Mr. Wills served as the President and Chief Operating Officer of Wills, Owens & Baker, P.C., a public accounting firm, from 1991 to 2000. Mr. Wills, a certified public accountant, earned his Bachelor of Science in accounting from West Chester University, and a Master of Science in taxation from Temple University.